RFC Study p53 Transmittal A

[Guest guest]

Dave, within your Fri., 12/12/08 posting, in re TP53 at 17p13.1 you

stated being " under the impression Fludarabine based treatments don't

work with these deletions. But according to this study, those with

the 17 deletion were included and had good results. Am I confusing

something here? "

For reference, the study you're referring to is that of recent posts

concerning the Roche sponsored CLL8 presentation at ASH 2008,

specifically reference Abstract nos. 325 & 781.

Abstract no. 325 notes that the study had two arms: FC and FCR. It

also states: " The overall incidences of trisomy 12 and abnormalities

of 13q, 11q23, and 17p13 detected by FISH were 12%, 57%, 25%, and 8%,

respectively, with no statistically significant differences between

treatment arms. " So for sake of argument, 8% each arm were 17p13.1

(TP53 loci). It's also rather moot since both arms received " F " . It

further states that of the 817 pts., for various stated broad

reasons, 56 were not evaluated for responses, leaving 761 that were

evaluated for responses; although 787 pts. were evaluated for PFS &

OS. From what I read, abstract no. 325 does not identify any stats

for 17p13.1 as to the 56 not evaluated, nor that proportion of ORR,

PR, nPR, CR, PFS, OS, et cetera.